Belite Bio, Inc
BLTE
$155.54
$3.572.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 12/31/2024 | 12/31/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 220.08% | 338.58% | 100.81% | 100.81% | 383.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 145.06% | 136.32% | 64.73% | 64.73% | 156.09% |
| Operating Income | -145.06% | -136.32% | -64.73% | -64.73% | -156.09% |
| Income Before Tax | -150.73% | -149.91% | -44.47% | -44.47% | -139.68% |
| Income Tax Expenses | -- | -- | -- | 100.00% | -- |
| Earnings from Continuing Operations | -150.73% | -149.91% | -44.49% | -44.49% | -139.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.73% | -149.91% | -44.49% | -44.49% | -139.58% |
| EBIT | -145.06% | -136.32% | -64.73% | -64.73% | -156.09% |
| EBITDA | -145.65% | -136.84% | -64.95% | -64.88% | -156.18% |
| EPS Basic | -117.82% | -130.87% | -30.05% | -30.01% | -89.55% |
| Normalized Basic EPS | -117.74% | -130.77% | -- | -30.07% | -- |
| EPS Diluted | -117.82% | -130.87% | -30.05% | -30.01% | -89.55% |
| Normalized Diluted EPS | -117.74% | -130.77% | -- | -30.07% | -- |
| Average Basic Shares Outstanding | 15.13% | 8.26% | 11.08% | 11.10% | 26.37% |
| Average Diluted Shares Outstanding | 15.13% | 8.26% | 11.08% | 11.10% | 26.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |